'Israeli intellectual property rights vulnerable'

May 1, 2007 16:18


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The US Federal Trade Commission has ruled that Israel will remain on its list of countries that do not protect intellectual property rights, Israel Radio reported on Tuesday. The organization has demanded that Israel, which aspires to join the Organization for Economic Cooperation and Development (OECD) - the organization of industrialized countries - fulfill the cooperative conditions of the trade agreement between Israel and the US. The Industry, Trade and Labor Ministry said that Israel abides by all international agreements it has signed, and offers satisfactory rights protection in all fields. The ministry said the situation was believed to be an issue of international disagreements over the correct way of supplying such protection, as well as the proper balance between various interests.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection